DexCom Inc. Stock Underperforms Tuesday When Compared To Competitors

enVVeno Medical Corp

Change company Symbol lookup

Select an option...

NVNO enVVeno Medical Corp

MTBC CareCloud Inc

WRK Westrock Co

SNDX Syndax Pharmaceuticals Inc

SLAMU Slam Corp

SURYY Sumitomo Realty & Development Co Ltd

MKKGY Merck KGaA

DAC Danaos Corp

YY JOYY Inc

MGU Macquarie Global Infrastructure Total Return Fund Inc.

Health Care : Health Care Equipment & Supplies | Small Cap Growth

Company profile

enVVeno Medical Corporation is a med-tech company. The Company is focused on improving the standard of care in the treatment of venous disease. The Company is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

DexCom Inc. Stock Underperforms Tuesday When Compared To Competitors

4:50 pm ET December 28, 2021 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of DexCom Inc. (DXCM) slid 7.09% to $529.50 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.26% to 36,398.21 and the S&P 500 Index falling 0.10% to 4,786.35. This was the stock's third consecutive day of losses. DexCom Inc. closed $129.95 short of its 52-week high ($659.45), which the company achieved on November 18th.

The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 0.40% to $170.35, Abbott Laboratories (ABT) fell 0.70% to $140.47, and Medtronic PLC (MDT) rose 0.10% to $104.53. Trading volume (755,076) eclipsed its 50-day average volume of 711,008.

Data source: Dow Jones Market Data, FactSet. Data compiled December 28, 2021.

-MarketWatch Automation

(END) Dow Jones Newswires

December 28, 2021 16:50 ET (21:50 GMT)